Bladder Cancer

+ -Text Size

Other Resources and References TOPICS

References: bladder cancer detailed guide

Advanced Bladder (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis of individual patient data. European Urology. 2005;48:189-201.

Advanced Bladder (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data. European Urology. 2005;48:202-206.

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

American Joint Committee on Cancer. AJCC Cancer Staging Manual. Urinary Bladder. 7th ed. New York, NY: Springer; 2010: 497-502.

Carmack AJK, Soloway MS. The diagnosis and staging of bladder cancer from RBCs to TURs. Urology. 2006;67 (suppl 3A): 3-10.

Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810-816.

Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2010/, based on November 2012 SEER data submission, posted to the SEER web site, April 2013.

International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol. 2011;29:2171-2177.

Kalsi J, Harland SJ, Feneley MR. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma. Expert Opin Drug Deliv. 2008;5:137-145.

Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374:239-249.

Lynch CF, Davila JA, Platz CE. Cancer of the urinary bladder. In: Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J, eds. SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

McDougal WS, Shipley WU, Kaufman DS, et al. Chapter 95: Cancer of the bladder, ureter and renal pelvis. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.

Moyer VA; US Preventive Services Task Force. Screening for bladder cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155:246-251.

National Cancer Institute. Physician Data Query (PDQ). Bladder Cancer Treatment. 2013. Accessed at www.cancer.gov/cancertopics/pdq/treatment/bladder/HealthProfessional on January 9, 2014.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. V.1.2014. Accessed at www.nccn.org/professionals/physician_gls/pdf/bladder.pdf on January 9, 2014.

Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342:1686-1692.

Smith A, Balar AV, Milowsky MI, Chen RC. Chapter 83 – Bladder Cancer. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.

Weight CJ, Garcia JA, Hansel DE, et al. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: A contemporary series. Cancer. 2009;15:792-799.


Last Medical Review: 02/26/2014
Last Revised: 02/26/2014